US Upholds $70m Hospira Epogen Verdict

Biosimilar Safe Harbors Need Record Of Non-Commercial Use, Ruling Suggests

 
• By Brenda Sandburg
  
Wollongong lighthouse providing safe harbor
Federal Circuit finds Hospira's Epogen biosimilar batches were outside safe harbor from infringement suit • Source: Shutterstock

More from Legal & IP

More from Generics Bulletin